Biotech Specialty Pharma


275 Grove Street, Suite 2-400
Newton, MA 02466 USA
Click for website

Research Sector Biotech Specialty Pharma

Summary Description Biopharmaceutical company dedicated to the development of treatments for two orphan diseases

Management Stephen R. Seiler, Founder, Chief Executive Officer; Warren C. Stern, Ph.D., Sr. Vice President of Drug Development; Maggie Flanagan LeFlore, Ph.D, Director; Colin Hill, Director; Mary K. Pendergast, Director

Click here for Financial Data
Keywords: orphan drug, sickle cell disease, inflammatory bowel disease, ulcerative colitis, pouchitis, radiation induced proctitis


Updated: Sept. 14, 2012


AesRx is a biopharmaceutical company dedicated to the development of two novel drugs, each of which targets an orphan disease.......view more

Products / Services

Aes-103 for Sickle Cell Disease and Aes-210 for inflammatory diseases of the lower bowel such as distal ulcerative colitis, pouchitis and radiation induced proctitis.......view more

Technology / Differentiation

AesRx believes its Aes-103 product for sickle cell is an attractive development opportunity because: (i) it has a well understood mechanism of action which has been validated in humans; (ii) it is ora...view more

Market / Customers

The primary market for Aes-103 for sickle cell disease (SCD) is the US (70,000-100,000 patients) and the EU (~40,000 patients). Secondary markets include the Middle East (~100,000 patients) and India......view more

Competitors / Substitutes / Alternatives

Although many agents have been studied the only disease modifying drug approved for the treatment of SCD is the anti-cancer agent hydroxyurea. However, hydroxyurea therapy can cause side effects that...view more


Aes-103 is currently in pre-clinical development. Human trials are scheduled to commence in summer 2011. AesRx will develop Aes-103 through the end of the first three human clinical trials in collab...view more